<DOC>
	<DOCNO>NCT02768519</DOCNO>
	<brief_summary>The purpose study determine indicative bioavailability single oral dose OTS167 , evaluate effect food OTS167 pharmacokinetics ( PK ) oral dosing . Eleven male female healthy participant age 45 year enter phase 1 , single-centre , double-blind , randomised , cross-over study . The trial design evaluate bioavailability OTS167 , effect food pharmacokinetics ( PK ) OTS167 administer oral route . Correlative study include evaluation safety endpoint examination , adverse event . This study involve 3 cohort evaluate safety tolerability oral dose low dose .</brief_summary>
	<brief_title>Study Evaluate Systemic Bioavailability Oral OTS167 Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Participants must meet follow criterion eligible participation study : 1 . Males female age 45 year . 2 . Female participant non‐childbearing potential , meet least one follow criterion : Amenorrhoeal 12 month ( menopause confirm Follicular Stimulating Hormone ( FSH ) Luteinising Hormone ( LH ) level define establish reference range ) , Surgically sterile ( e.g . hysterectomy , oophorectomy , tubal ligation ) least past 3 month . 3 . Able communicate site personnel understand voluntarily sign Informed Consent Form ( ICF ) . 4 . Able willing comply protocol , include availability schedule study visit . 5 . Body mass index ( BMI ) 18 kg/m2 30 kg/m2 ( inclusive ) 6 . No clinically significant abnormality determine medical history , physical examination , blood chemistry , hematology , urinalysis , 12lead electrocardiogram ( ECGs ) . 7 . If male , agree use medically acceptable method contraception Screening 7 day administration last dose study drug . Medically acceptable method contraception include follow : abstinence ; medically approve hormonal method ; condom ; diaphragm ; intrauterine device . This requirement may waive Principal Investigator delegate satisfy participant partner sterile ( i.e. , female undergone hysterectomy , undergone tubal ligation least 3 month prior Screening , postmenopausal [ menstrual period least 12 month prior Screening ] ; male , undergone vasectomy least 6 month prior Screening ) . Male participant agree donate sperm least 90 day [ 3 month ] administration last dose study drug . 8 . Agree avoid drinking alcohol within 72 hour prior checkin clinical facility . 9 . Adequate venous access leave right arm allow collection number blood sample . Participants meet follow criterion ineligible participation study . 1 . Evidence history clinical significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic diseases 2 . Orthostatic blood pressure change ( &gt; 15mmHg ) symptom , presence uncontrolled hypertension ( SBP &gt; 160 mmHg diastolic &gt; 95 mmHg ) screening , admission ( Day 1 ) predose ( Day 1 ) . 3 . Greater 2 standard drink per day , average , men woman , history drug alcohol addiction abuse within last 5 year . 4 . History allergic , anaphylaxis hypersensitivity OTS167 excipients content Humco ™ cherry syrup . 5 . Female participant currently lactate . 6 . Donated either blood plasma ( e.g. , plasmapheresis ) within 6 week prior dose Period 1 . All participant must advise donate either blood plasma least 6 week complete study . 7 . Use prescription medication ( exception contraceptive ) , overthecounter medication ( exception paracetamol [ &lt; 2 gm/day ] singledose daily multivitamin ) , herbal medication product contain herbal extract within 14 day prior first dose . 8 . Positive result illicit drug test alcohol breath test screen admission . 9 . Positive screen test HIV antibody , Hepatitis B surface antigen Hepatitis C antibody . 10 . Use investigational drug within last 30 day within period 5 time drug 's halflife , whichever longer , current participation investigational protocol . 11 . Participants , opinion Principal Investigator delegate , participate study capable follow study schedule reason . 12 . Either QTcF &gt; 450 HR &lt; 40 &gt; 100 screening , admission ( Day1 ) predose ( Day 1 ) . Test may repeat discretion investigator obtain average order confirm eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Participants</keyword>
</DOC>